132 related articles for article (PubMed ID: 35612608)
1. Combination of multiple methods and views for recognition, transportation, and structure-guided modification of lysine-specific demethylase phenylcyclopropylamine inhibitor.
Liu X; Zhang Z; She N; Zhai J; Zhao Y; Wang C
Phys Chem Chem Phys; 2022 Jun; 24(22):13806-13823. PubMed ID: 35612608
[TBL] [Abstract][Full Text] [Related]
2. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM
J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
Ding L; Wang ZZ; Sun XD; Yang J; Ma CY; Li W; Liu HM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3521-3528. PubMed ID: 28610981
[TBL] [Abstract][Full Text] [Related]
4. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
5. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Binding Mode of Reversible LSD1 Inhibitors Derived from Stilbene Derivatives by 3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation.
Xu Y; He Z; Yang M; Gao Y; Jin L; Wang M; Zheng Y; Lu X; Zhang S; Wang C; Zhao Z; Zhao J; Gao Q; Duan Y
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817721
[TBL] [Abstract][Full Text] [Related]
7. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
Schmidt DM; McCafferty DG
Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
10. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
[TBL] [Abstract][Full Text] [Related]
11. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide.
Kakizawa T; Mizukami T; Itoh Y; Hasegawa M; Sasaki R; Suzuki T
Bioorg Med Chem Lett; 2016 Feb; 26(4):1193-5. PubMed ID: 26794039
[TBL] [Abstract][Full Text] [Related]
13. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations.
Zhang X; Li M; Wang Y; Zhao Y
J Recept Signal Transduct Res; 2015; 35(5):363-9. PubMed ID: 26364657
[TBL] [Abstract][Full Text] [Related]
14. Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.
Zhang X; Sun Y; Zhang Z; Wang H; Wang J; Zhao D
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129990. PubMed ID: 34390793
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1.
Zhang X; Yan J; Wang H; Wang Y; Wang J; Zhao D
J Biomol Struct Dyn; 2021 Mar; 39(4):1189-1202. PubMed ID: 32036765
[TBL] [Abstract][Full Text] [Related]
17. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
19. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
[TBL] [Abstract][Full Text] [Related]
20. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
